Agios Pharmaceuticals Operating Income 2012-2024 | AGIO

Agios Pharmaceuticals operating income from 2012 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Agios Pharmaceuticals Operating Income 2012-2024 | AGIO

Agios Pharmaceuticals operating income from 2012 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$204.2B
Stryker (SYK)$146.7B
Boston Scientific (BSX)$132.6B
EssilorLuxottica (ESLOY)$112.1B
Medtronic (MDT)$110.6B
Haleon (HLN)$43.7B
Lonza Group Ag (LZAGY)$42.2B
GE HealthCare Technologies (GEHC)$37.7B
ResMed (RMD)$35.8B
Terumo (TRUMY)$29.7B
Koninklijke Philips (PHG)$24.8B
Zimmer Biomet Holdings (ZBH)$21.9B
Insulet (PODD)$18.4B
Baxter (BAX)$17B
Smith & Nephew SNATS (SNN)$11.1B
BellRing Brands (BRBR)$10.2B
Bio-Rad Laboratories (BIO)$9.3B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$6.3B
TG Therapeutics (TGTX)$5.5B
Haemonetics (HAE)$4.3B
Prestige Consumer Healthcare (PBH)$4.2B
ICU Medical (ICUI)$4.1B
Perrigo (PRGO)$3.8B
Envista Holdings (NVST)$3.7B
Neogen (NEOG)$3.2B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.8B
QuidelOrtho (QDEL)$2.7B
LeMaitre Vascular (LMAT)$2.4B